1. AT1R–EGFR transactivation occurs in HMEC-LST-AT1R cells.
AT1R–EGFR transactivation occurs in HMEC-LST-AT1R cells. (A) HMEC-LST cells (mCherry or AT1R transduced) were serum starved then stimulated with 100 nM AngII for 5-10 minutes. Robust activation of the EGFR (pY1068) and ERK1/2 was observed in the AT1R-transduced cells. (B,C) Quantification of western blot data using densitometry analysis (ImageJ) illustrates increases in phospho-EGFR (pY1068; B) and phospho-ERK1/2 (C) upon stimulation with AngII (n = 4 experiments; *P = 0.0137, **P = 0.0028, paired two-tailed Student's t-test). (D) HMEC-LST-AT1R cells were treated with 5 µM AG1478 (EGFR inhibitor) or 1 µM candesartan cilexetil (AT1R antagonist) for 30 minutes prior to stimulation with 100 nM AngII for 5-10 minutes. Analysis revealed that inhibition of either EGFR or AT1R activity blocks AngII-mediated AT1R–EGFR transactivation (n = 3 experiments; a representative western blot is shown).
Amee J. George et al. J Cell Sci 2013;126:
© Published by The Company of Biologists Ltd